Hi everyone,
My name’s Kira and I work in the Policy, Evidence and Influencing team at Breast Cancer Now.
We’re looking to hear from anyone who has received the treatment ribociclib (Kisqali) with an aromatase inhibitor for adjuvant treatment of hormone receptor positive, HER2-negative early breast cancer at a high risk of recurrence. The treatment is being assessed by the Scottish Medicines Consortium (SMC) to see if it should be made available through NHSScotland and we would love to hear your views to help shape our submission.
We’re looking to hear from people who have experience of this treatment for primary breast cancer, for example you may have received the treatment through the clinical trial, be receiving the treatment privately or have access on the NHS in another part of the UK. We’re also looking for people who might benefit from this treatment if it were to be approved for use on NHSScotland.
It’s crucial that the SMC hears the voices of patients as part of their assessment. If you’d like to share your views on this treatment, please email policy@breastcancernow.org.
Your views will be shared completely anonymously.
Thank you!
Kira